Kidney Disease Costs Keeping You From Care? What You Need to Know
"A deep dive into how out-of-pocket expenses impact treatment for chronic kidney disease and what it means for your health."
Chronic kidney disease (CKD) is a major global health concern, responsible for over a million deaths each year. Managing CKD often requires multiple medications and long-term treatments, which can create significant financial strain on individuals and their families.
While the importance of accessible healthcare is globally recognized, high out-of-pocket costs can severely limit access to necessary treatments. A recent study investigated the impact of these costs on treatment commencement and adherence for CKD patients, shedding light on who is most affected and why.
This article breaks down the findings of this critical research, exploring how financial burdens affect CKD treatment and what can be done to improve access for those in need.
CKD by the Numbers
Chronic kidney disease (CKD) is a type of long-term kidney disease, defined by abnormal kidney function and/or structure that must be present for at least three months to meet the criteria for CKD. The CDC reports that an estimated 4 in 10 adults with diabetes have chronic kidney disease, noting that damaged kidneys may not clean the blood as effectively as healthy kidneys over time. The NIDDK tracks kidney disease statistics for the United States, covering both chronic kidney disease and end-stage kidney disease (ESKD). These figures make clear that CKD is a widespread condition concentrated in high-risk groups such as people living with diabetes.
How CKD Is Treated Today
Standard care for chronic kidney disease centers on treatment that can slow the progression of the disease, since CKD usually worsens over time even as the severity varies from person to person. Mayo Clinic estimates that CKD affects about one in seven American adults, characterizing the condition as progressive damage and loss of function in the kidneys. To make research more meaningful, the SONG-CKD initiative works to establish standardised core outcomes for chronic kidney disease trials, so studies measure results that matter to patients and clinicians. Despite these tools, an overview of the field notes that the World Health Organization projects CKD will become the fifth most common chronic disease in the world by 2040, underscoring the limits of current prevention and treatment efforts.
Foundations of the Modern CKD Definition
A foundational milestone in modern kidney medicine is the working definition of CKD as abnormal kidney function or structure present for more than three months, a condition estimated to affect roughly 9 to 13 percent of the adult population worldwide. The condition is understood as a gradual loss of kidney function over time, most often caused by diabetes and high blood pressure. Harvard Health explains that healthy kidneys filter blood, remove waste, balance electrolytes, and help control blood pressure, and that CKD develops when the kidneys are damaged and slowly lose this ability. Together these sources reflect the core medical understanding of CKD: a progressive decline in normal kidney structure and function that unfolds over months and years.
The True Cost of Kidney Disease Treatment
The study systematically reviewed existing research to understand how the financial burden of CKD treatment affects patients' decisions to start and continue care. Researchers looked for studies that examined the link between treatment costs, medication expenses, and patients either forgoing or stopping treatment.
- Cost as a Barrier: High costs prevent many from starting treatment.
- Non-Adherence: Financial strain leads to skipping medication or dialysis sessions.
- Discontinuation: Patients are forced to stop treatment altogether due to costs.
- Poorer Households: Those with limited financial resources are disproportionately affected.
What the Latest Research Shows
The definition and classification of chronic kidney disease have evolved over time, and current international guidelines define the condition as a glomerular filtration rate (GFR) below 60 mL/min per 1.73 m2 or the presence of markers of kidney damage. GFR-based staging is central to clinical practice, and a person with stage 4 CKD has advanced kidney damage with a severe decrease in GFR. Both sources agree that measuring GFR remains the cornerstone for classifying CKD severity and guiding treatment decisions as the disease progresses.
Where Standard Care Falls Short
Early treatment for chronic kidney disease is often overlooked during routine clinical care, and this gap in care is a significant failure of the standard approach. Rappler reports that as many as one-third of patients with kidney failure have no record of health care treatment for their kidneys in the early stages of their disease. By the time kidney disease is finally addressed, many patients have already progressed to kidney failure, a loss that might have been prevented with earlier intervention.
CKD vs. Acute Kidney Injury
CKD is frequently compared with acute kidney injury (AKI), and side-by-side comparisons distinguish the two across onset, reversibility, kidney size, laboratory findings, and treatment priorities, drawing on the KDIGO 2012/2022 CKD guidelines, the KDIGO 2012 AKI guidelines, and the National Kidney Foundation. A separate analysis points out that the creatinine-based eGFR equations used in the United States historically included a race index for Black Americans that inflated the eGFR value by as much as 16% compared with non-Black Americans with the same serum creatinine, raising questions about equity in how kidney function is measured. Beyond classification, chronic kidney disease affects life expectancy at all stages, with outcomes depending on how effectively the condition is managed through lifestyle changes and treatment.
The Path Forward: Addressing the Financial Burden
The study highlights the urgent need to address the financial barriers to CKD treatment. By expanding insurance coverage, providing financial assistance, and implementing policies that reduce out-of-pocket costs, healthcare systems can improve access to life-saving treatments and reduce the burden of this devastating disease.
What Experts Are Saying
When clinical trial data leave uncertainty, expert opinion can help fill the gaps: one research group developed a method that formally incorporates elicited expert opinion in a Bayesian analysis and used it to extrapolate survival in the placebo arm of DAPA-CKD, a phase 3 trial of dapagliflozin in patients with chronic kidney disease. Dapagliflozin, marketed as Farxiga, has been examined in CKD clinical trials for its potential benefits and risks in managing the condition. Beyond drug therapy, clinical experts also address day-to-day management, such as the usefulness of both cardiovascular and resistance exercise for people living with CKD.
Looking Ahead in CKD Care
Chronic kidney disease is a long-term condition in which the kidneys do not work as well as they should, usually caused by other conditions that put a strain on the kidneys, and often by a combination of different problems. It represents a growing global health burden, with increasing mortality and disability-adjusted life years, and vitamin D deficiency is highly prevalent among CKD patients and closely associated with decreased renal function. New modelling from AstraZeneca offers a first-ever 10-year outlook on the impact of CKD across clinical, economic, societal, and environmental dimensions, providing insight for the United States, Brazil, the United Kingdom, Spain, and Germany.
The Silent Epidemic
Kidney disease is often called a silent condition because it develops gradually, and many people are unaware that their kidneys are being damaged until the disease becomes advanced. In the United States, chronic kidney disease affects approximately 37 million Americans, yet an estimated 90% of people with the condition do not know they have it, in part because the kidneys have remarkable compensatory abilities and can continue functioning even when significantly damaged. When kidney function is lost, toxins accumulate in the body, which can trigger a number of additional disorders. The combination of silent onset and widespread lack of awareness is a major systemic barrier to early diagnosis.
The Toll on Real Lives
Chronic kidney disease is currently the ninth leading cause of death globally and is projected to become the fifth leading cause by 2040. In Australia, it is estimated that 2.7 million people have biomedical markers of CKD, yet fewer than 10 percent are aware they have the condition. CKD remains a major global health issue affecting millions, presenting persistent diagnostic and therapeutic challenges. Because the disease is heterogeneous and progressive, researchers are exploring approaches such as integrating genetic testing with real-world clinical insights to better understand who responds to treatment.